Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.32 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.32 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL323060 | 1.00 | CHRM2 (0.44) | CHRM2CHRM4CHRM5CHRM3CYP1A2 | |
| SCHEMBL323220 | 1.00 | CHRM2 (0.44) | CHRM2CHRM4CHRM5CHRM3CYP1A2 | |
| Water SCHEMBL4817063 | 0.98 | CHRM2 (0.42) | CHRM2CHRM4CHRM5CHRM3CYP1A2 | |
| SCHEMBL10306685 | 0.98 | CHRM2 (0.42) | CHRM2CHRM4CHRM5CHRM3CYP1A2 | |
| Benzene SCHEMBL5878128 | 0.96 | CHRM2 (0.41) | CHRM2CHRM4CHRM5CHRM3CYP1A2 | |
| Isobutane SCHEMBL11057630 | 0.92 | CHRM2 (0.43) | CHRM2CHRM4CHRM5CHRM3CYP1A2 | |
| Hexane SCHEMBL11488442 | 0.89 | CHRM2 (0.41) | CHRM2CHRM4CHRM5CHRM3CYP1A2 | |
| SCHEMBL8207932 | 0.84 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM3FEN1 | |
| Toluene SCHEMBL1308697 | 0.83 | ALDH1A1 (0.43) | CHRM2CHRM4CHRM5CHRM3FEN1 | |
| Benzene SCHEMBL11465351 | 0.82 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116270660-A | Bcl-2/Bcl-xl inhibitor-containing composition and preparation method and application thereof | 广州麓鹏制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116236583-A | Bcl-2/Bcl-xl inhibitor-containing composition and preparation method and application thereof | 广州麓鹏制药有限公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-115484933-A | Hot melt extrusion solid dispersions containing BCL2 inhibitors | 广州麓鹏制药有限公司 | 2022-12-16 | — | — | CN | disclosed |
| EP-2675798-B1 | NOVEL BENZODIOXOLE PIPERAZINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2015-07-01 | — | — | EP | disclosed |
| EP-2590984-B1 | ANELLATED PYRIDINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2015-01-28 | — | — | EP | disclosed |
| US-8877778-B2 | Benzofurane compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2582705-B1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8722683-B2 | Benzodioxole piperazine compounds | HOFFMANN LA-ROCHE INC. (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2675798-A1 | NOVEL BENZODIOXOLE PIPERAZINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-25 | — | — | EP | disclosed |
| US-8586579-B2 | Anellated pyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2590984-A1 | ANELLATED PYRIDINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| EP-2582705-A1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| US-20130040948-A1 | NOVEL BENZODIOXOLE PIPERAZINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | US | disclosed |
| WO-2012110470-A1 | NOVEL BENZODIOXOLE PIPERAZINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-23 | — | — | WO | disclosed |
| US-20120157449-A1 | BENZOFURANE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2012080149-A1 | NOVEL BENZOFURANE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012004206-A1 | ANELLATED PYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010201-A1 | NOVEL ANELLATED PYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-01-12 | — | — | US | disclosed |
| WO-2011161009-A1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-29 | — | — | WO | disclosed |
| US-20110313151-A1 | ANELLATED PYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157449-A1 | BENZOFURANE COMPOUNDS | HTR3A, HTR3C, HTR2A | CHRM2 255/4885CHRM4 411/4885CHRM5 275/4885 |
| US-20130040948-A1 | NOVEL BENZODIOXOLE PIPERAZINE COMPOUNDS | HTR2A, HTR2C, HTR5A | CHRM2 152/4885CHRM4 500/4885CHRM5 224/4885 |
| US-20120010201-A1 | NOVEL ANELLATED PYRIDINE COMPOUNDS | ADORA3, ADORA2A, HTR3A | CHRM2 121/4885CHRM4 206/4885CHRM5 175/4885 |
| US-20110313151-A1 | ANELLATED PYRIDINE COMPOUNDS | ADORA3, ADORA2A, HTR3A | CHRM2 104/4885CHRM4 202/4885CHRM5 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.